REDUCTIONNCT07917078
Reduced-Dose Thrombolysis in Intermediate-Risk Pulmonary Embolism With High-Risk Features
StatusNot Yet Recruiting
PhasePhase 3
Primary completion (estimated)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 1 version: 1 with changes below.
- Study First Submitted
Endpoints
Primary
Change in the ratio of right ventricular end-diastolic diameter to left ventricular end-diastolic diameter (RVED/LVED) as measured by echocardiography
Timeframe: Between baseline and 48 hours
Secondary (12)
Change in the ratio of right ventricular end-diastolic diameter to left ventricular end-diastolic diameter (RVED/LVED) as measured by echocardiography
Clinical Deterioration
PE-Related Death
All cause Death
Recurrent PE
Show 7 moreShow less
Persistent Dyspnea
Functional outcome
Persistent Right Ventricular Dysfunction
Chronic thromboembolic pulmonary disease (CTEPD) and/or Chronic thromboembolic pulmonary hypertension (CTEPH)
Major bleeding
Clinically relevant non-major bleeding
Minor bleeding
Arms and interventions
Reduced-Dose Alteplase and Standard AnticoagulationActive comparator
Low-molecular-weight heparin (LMWH) or unfractionated heparin (UFH) and reduced-dose alteplase \[25 mg continuous intravenous infusion for 2 hours\]
Standard AnticoagulationActive comparator
Low-molecular-weight heparin (LMWH) or unfractionated heparin (UFH)
Drugs: Alteplase, Standard Anticoagulation
Sites
26 sites in 1 country